New treatment option arrives for Canadians with sleep apnea and obesity
June 22, 2026
June 22, 2026
Health Canada has approved Zepbound (tirzepatide) as the first medication in Canada indicated for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults living with obesity.
The approval marks a new development in the treatment of a condition that affects breathing during sleep and can contribute to a range of health complications, including cardiovascular disease, Type 2 diabetes and daytime fatigue. OSA occurs when the upper airway becomes blocked during sleep, causing repeated interruptions in breathing throughout the night.
The medication is approved for use alongside a reduced-calorie diet and increased physical activity in adults with a body mass index of 30 or higher.
For patients living with both obesity and sleep apnea, the relationship between the two conditions can be difficult to break, according to Dr. Paulette Pillersdorf, a dentist and snoring and sleep apnea therapist.
Mainstream NewsBed Bug Infestation Forces Closure of Fort Simpson Schools
Two schools in Fort Simpson, N.W.T., will close starting Monday due to a bed bug infestation, with no confirmed reopening date.
Mainstream NewsThe Complex History of Bible Translations in Greenland and Labrador
Early Christian missionaries in Greenland and Labrador relied on Inuit converts to translate the Bible, revealing a complex interplay of cultural exchange and religious adaptation.
Mainstream NewsInuit-Led Pirutsiagutiit Program Replaces Child First Initiative
Federal government transfers $575M in child health and social support funding to Inuit organizations, ending uncertainty over previous program.
Mainstream NewsWhitehorse Students Engage With Canadian Astronauts Aboard the ISS
Students from Whitehorse schools connected with Canadian astronauts Jenni Gibbons and Joshua Kutryk, gaining insights into space exploration and inspiring future careers in science.